Toggle Health Problems and D

Better Cancer survival if higher vitamin D a decade earlier (esp. Melanoma, Kidney, Prostate)– Aug 2018

Circulating 25-hydroxyvitamin D up to 3 decades prior to diagnosis in relation to overall and organ-specific cancer survival.

Eur J Epidemiol. 2018 Nov;33(11):1087-1099. doi: 10.1007/s10654-018-0428-2.


Mortality is.gd/VitaminDMortality
click on image for details
The TOP articles in Mortality and Vitamin D are listed here:

The study on this page did not mention Breast Cancer

The study on this page did not mention Lung Cancer

Note: Vitamin D also reduces the chance of getting cancer

derived from Grassroots 2013

Items in both categories Cancer and Mortality are listed here:

PDF is available free at Sci-Hub  10.1007/s10654-018-0428-2

It is Interesting that this study was funded by the US govt but the publisher charges $39 for the taxpayers to see it

Vitamin D levels were measured ~ a decade before Cancer diagnosis
This chart shows the mortality after Cancer diagnosis


Weinstein SJ1, Mondul AM2, Yu K3, Layne TM3, Abnet CC3, Freedman ND3, Stolzenberg-Solomon RZ3, Lim U4, Gail MH3, Albanes D3.

  • 1 Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, 9609 Medical Center Drive, Bethesda, MD, 20892, USA. weinstes at mail.nih.gov.
  • 2 Department of Epidemiology, School of Public Health, University of Michigan, Ann Arbor, MI, USA.
  • 3 Division of Cancer Epidemiology and Genetics, National Cancer Institute, NIH, Department of Health and Human Services, 9609 Medical Center Drive, Bethesda, MD, 20892, USA.
  • 4 Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, HI, USA.

While vitamin D has been associated with improved overall cancer survival in some investigations, few have prospectively evaluated organ-specific survival. We examined the accepted biomarker of vitamin D status, serum 25-hydroxyvitamin D [25(OH)D], and cancer survival in the Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study.
Of 4616 cancer cases with measured serum 25(OH)D, 2884 died of their cancer during 28 years of follow-up and 1732 survived or died of other causes.
Proportional hazards regression estimated hazard ratios (HR) and 95% confidence intervals (CI) for the association between pre-diagnostic 25(OH)D and overall and site-specific survival. Serum 25(OH)D was significantly lower among cases who subsequently died from their malignancy compared with those who did not (medians 34.7 vs. 36.5 nmol/L, respectively; p = 0.01). Higher 25(OH)D was associated with lower

  • overall cancer mortality (HR = 0.76, 95% CI 0.67-0.85 for highest vs. lowest quintile, p-trend < 0.0001).

Higher 25(OH)D was related to lower mortality from the following site-specific malignancies:

  • prostate (HR = 0.74, 95% CI 0.55-1.01, p-trend = 0.005),
  • kidney (HR = 0.59, 95% CI 0.35-0.98, p-trend = 0.28), and
  • melanoma (HR = 0.39, 95% CI 0.20-0.78, p-trend = 0.01),

but increased mortality from lung cancer (HR = 1.28, 95% CI 1.02-1.61, p-trend = 0.19).
Improved survival was also suggested for

  • head and neck,
  • gastric,
  • pancreatic, and
  • liver cancers,

though not statistically significantly, and case numbers for the latter two organ sites were small.

Higher 25(OH)D status years prior to diagnosis was related to improved survival for overall and some site-specific cancers, associations that should be examined in other prospective populations that include women and other racial-ethnic groups.

Created by admin. Last Modification: Tuesday November 20, 2018 14:03:47 GMT-0000 by admin. (Version 10)

Attached files

ID Name Comment Uploaded Size Downloads
10875 Cancer mortality.jpg admin 20 Nov, 2018 36.39 Kb 679